available 24/7
available 24/7
partner
Ranbaxy, a generic drug maker, pleaded guilty to federal drug safety violations on Monday and agreed to pay $500 million in fines to resolve claims that it sold subpar drugs and made false statements to the Food and Drug Administration regarding its manufacturing processes.
Ranbaxy acknowledged that it failed to conduct proper safety and quality tests of several drugs manufactured at its plants in India. The drugs included several common types of medicines like Gabapentin, a drug used to treat epilepsy, and the antibiotic ciproflaxacin.
The company admitted that in 2007 it had known that certain batches had “unknown impurities” and unreliable shelf lives, but delayed the recall for at least a month which involved more than 73 million pills.
Ranbaxy will pay $150 million in a criminal fine and the remainder will go to settle civil claims brought by the federal government and all 50 states.
If you have become the victim of a dangerous or defective pharmaceutical drug, contact a personal injury lawyer from PKSD today. Our award winning lawyers charge no upfront fees if we take on your case and your initial consultation is also free of charge.
PKSD – Est. 1999. Ph: 414-333-3333.
This page has been written, edited, and reviewed by a team of legal writers following our comprehensive editorial guidelines. This page was approved by attorney Jeffery A. Pitman, who has more than 28 years of legal experience and handled thousands of personal injury cases while obtaining millions of dollars in verdicts and settlements in Wisconsin, Illinois, Iowa and New Mexico.
In this month’s edition of the PKSD Newsletter, You Should Know, we cover the opioid epidemic and the lawsuits being filed by state, county...
The following products have been recalled by the FDA for various reasons. For more information, please go to www.fda.gov. Rushing Waters Fisheries, Palmyra, is...
A new report released by the Government Accountability Office (GAO) reveals disturbing gaps in the the Food and Drug Administrations (FDA) tracking of drug...
